Publications by authors named "Jun Kunitomo"

Claim this Profile
D
Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes.
Yoshihiro Banno, Shigekazu Sasaki, Makoto Kamata, Jun Kunitomo, Yasufumi Miyamoto

Bioorg Med Chem· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.
Masato Yoshikawa, Takenori Hitaka, Tomoaki Hasui, Makoto Fushimi, Jun Kunitomo

Bioorg Med Chem· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.
Masato Yoshikawa, Haruhi Kamisaki, Jun Kunitomo, Hideyuki Oki, Hironori Kokubo

Bioorg Med Chem· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
Jun Kunitomo, Masato Yoshikawa, Makoto Fushimi, Akira Kawada, John F Quinn

J Med Chem· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities.
Shizuo Kasai, Makoto Kamata, Shinichi Masada, Jun Kunitomo, Masahiro Kamaura

J Med Chem· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Tomohiro Onishi, Hiroki Iwashita, Yumiko Uno, Jun Kunitomo, Morihisa Saitoh

J Neurochem· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists.
Tatsuhiko Fujimoto, Jun Kunitomo, Yoshihide Tomata, Keiji Nishiyama, Masato Nakashima

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists.
Tatsuhiko Fujimoto, Yoshihide Tomata, Jun Kunitomo, Mariko Hirozane, Shogo Marui

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enantioselective synthesis of the novel chiral sulfoxide derivative as a glycogen synthase kinase 3beta inhibitor.
Morihisa Saitoh, Jun Kunitomo, Eiji Kimura, Toru Yamano, Fumio Itoh

Chem Pharm Bull (Tokyo)· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability.
Morihisa Saitoh, Jun Kunitomo, Eiji Kimura, Hiroki Iwashita, Yumiko Uno

J Med Chem· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
Morihisa Saitoh, Jun Kunitomo, Eiji Kimura, Yoji Hayase, Hiromi Kobayashi

Bioorg Med Chem· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis